Bright Minds Biosciences Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	Sep '19 Sep 30, 2019
Net Income	-3.58	-7.37	-14.96	-8.65	-0.48	-0.24
Depreciation & Amortization	0.07	0.07	0.01	-	-	-
Asset Writedown & Restructuring Costs	-	-	0	-	-	-
Stock-Based Compensation	1.03	1.15	0.9	0.88	0.16	-
Other Operating Activities	0.2	0.07	-0.26	0.14	-	-
Change in Accounts Payable	-0.48	-1.2	0.77	0.51	0.11	0.11
Change in Other Net Operating Assets	0.17	0.26	-0.04	-0.2	-0.08	-
Operating Cash Flow	-2.58	-7.02	-13.59	-7.32	-0.29	-0.13
Long-Term Debt Repaid	-	-0.09	-0.01	-	-	-
Net Debt Issued (Repaid)	-0.09	-0.09	-0.01	-	-	-
Issuance of Common Stock	0.9	1.47	6	27.84	1.01	0.37
Other Financing Activities	-	0.8	-0.8	-1.79	-	-
Financing Cash Flow	0.81	2.19	5.2	26.06	1.01	0.37
Foreign Exchange Rate Adjustments	-0.17	-0.05	0.26	0.22	-	-
Net Cash Flow	-1.94	-4.88	-8.13	18.96	0.72	0.24
Free Cash Flow	-2.58	-7.02	-13.59	-7.32	-0.29	-0.13
Free Cash Flow Per Share	-0.63	-1.89	-5.50	-4.08	-0.40	-0.30
Levered Free Cash Flow	-1.34	-4.22	-7.58	-3.85	-0.1	-
Unlevered Free Cash Flow	-1.33	-4.22	-7.58	-3.85	-0.1	-
Change in Net Working Capital	0.31	0.94	-0.72	-0.29	-0.04	-

Source: S&P Capital IQ. Standard template. Financial Sources.